Spinal cord stimulation plus rehabilitation for severe chronic neuropathic leg pain
Official title: An Integrated Intervention of Spinal Cord Stimulation and Multidisciplinary Rehabilitation for Chronic Neuropathic Leg Pain: A Single-case Experimental Design Protocol
Run by Oslo University Hospital · NCT07403331 · Data updated 2026-11-12
This project will try combining spinal cord stimulation with a multidisciplinary rehabilitation program to reduce severe nerve pain and improve physical function in adults with chronic neuropathic leg pain.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Oslo University Hospital Academic / other |
| Locations | 1 site (Oslo) |
| Status | Recruiting |
| Started | May 4, 2026 |
| Main results expected | April 1, 2027 |
| Study ends | July 1, 2027 |
| Registry record updated | October 16, 2026 |
| Trial ID | NCT07403331 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 18–60 with chronic (>6 months) peripheral neuropathic pain mainly in one or both legs (post‑spinal pain syndrome or localized nerve damage) who have tried standard treatments, can travel to Oslo, speak Norwegian, and can operate an SCS device.
✕Probably not a fit
Patients whose pain is not primarily in the legs, who have widespread non‑neuropathic pain, cannot travel to Oslo, lack Norwegian language skills, have cognitive impairment, exceed opioid limits (>50 mg OMEQ daily), or have ongoing compensation/claims issues may not benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-case experimental design uses repeated measurements within each participant to compare a pre-implant baseline, a randomized short waiting period after implantation, a 12-week active treatment phase combining spinal cord stimulation (SCS) and multidisciplinary rehabilitation, and a five-week follow-up about six months after implantation. Phase A1 is the baseline, A2 is a randomized 2–4 week waiting period, B is the 12‑week SCS+rehabilitation phase (analyzed as early B1 and later B2), and FU is the follow-up period. Primary contrasts are predefined as A1 vs B1 for leg pain intensity and A1 vs B2 for physical function (PROMIS-29), with repeated within-patient measures allowing phase-to-phase comparisons. Eligible participants are adults 18–60 with dominant peripheral neuropathic pain in one or both legs who have tried prior treatments and can attend the Oslo center and use the SCS device.
Why it matters
Potential benefit: If successful, the combined SCS and multidisciplinary program could meaningfully reduce leg neuropathic pain and improve daily physical function and coping.
How similar studies have gone: Previous studies indicate SCS can relieve post‑surgical or injury‑related neuropathic leg pain and multidisciplinary care helps long‑term pain, but combining SCS with a multidisciplinary rehabilitation bundle has not been published.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: * Peripheral neuropathic pain in one or both legs for \>6 months due to: * (1) Post Spinal Pain Syndrome (type 1 or 2). * (2) Localized nerve damage. * The area of the neuropathic pain in the leg(s) must be the dominant pain component. * Age ranges from 18-60 years. * Previous standard conservative (or surgical) treatment attempted. * Opioid use within permissible limits at implantation time (daily opioid dose \<50 mg OMEQ). * Willingness to actively participate in the treatment bundle. * Living within reasonable travelling distance from Oslo. * Proficiency in understanding oral and written Norwegian, essential to benefit from the program that relies on mutual comprehension, nuanced conversation, and emotional expression, which are language-dependent. * Cognitive capacity to provide informed consent. * Ability to master the technical aspects of the SCS system (switching programs on the remote control). Exclusion criteria: * Currently undergoing the claims process for health benefits (e.g., disability pensions from NAV (Norwegian Labour and Welfare Administration). * Presenting a psychological or psychiatric disorder that may impact treatment efficacy. * Chronic generalized pain conditions. * Other pain conditions in the affected area, such as osteoarthritis. * Pregnancy.
Where it's running
-
Department of pain management and research, Oslo university hospital
Oslo, Norway Recruiting
Study contacts
- Principal investigator: Lars-Petter Granan, Ph.D — Department of pain management and research, Oslo university hospital
- Study coordinator: Christopher Ekholdt, PhD-student
- Email: chrekh@ous-hf.no
- Phone: +4723026161
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Immune and signaling markers in blood and spinal fluid during spinal cord stimulation for neuropathic pain
This project tests whether measuring immune and signaling molecules in blood and cerebrospinal fluid can help explain and predict how spinal cord stimulation works for adults with chronic neuropathic pain.
-
Quiet Knee Protocol after knee replacement
A randomized study tests whether a Quiet Knee Protocol after unilateral knee replacement helps with pain, range of motion, and recovery better than standard rehab.
-
Neuropathic Pain Severity in Lumbar Spinal Stenosis and Its Link to Radiology
This study will test how severe neuropathic pain is in adults with lumbar spinal stenosis and see if it relates to MRI findings and other clinical features.
-
Virtual Reality-Based Hypnotherapy to Help Pain, Sleep, and Mood in Spinal Cord Injury
Adults with spinal cord injury will try adding short VR-based hypnotherapy sessions to their standard physiotherapy to see if it reduces pain and improves sleep and mood.
-
Immersive Virtual Reality and Exercise Programs for Multiple Sclerosis
Aims to see if a VR-based exercise program helps adults with MS improve mobility and fitness.
-
Extended-release Pregabalin for nerve pain from diabetes or shingles
This phase 3 study tests an extended-release form of pregabalin to see if it reduces nerve-pain symptoms in adults with diabetic neuropathy or postherpetic neuralgia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.